Barclays’s Thorne Healthtech, Inc. Common Stock THRN Stock Holding History

Barclays’s Portfolio THRN Stock Details THRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-51,089	Closed	-$521K	–	5446
2023 Q3	$521K	Buy	51,089 +41,693	+444%	+$317K	﹤0.01%	2789
2023 Q2	$44.2K	Sell	9,396 -4,365	-32%	-$20.1K	﹤0.01%	3894
2023 Q1	$63.6K	Buy	13,761 +3,477	+34%	+$15.3K	﹤0.01%	4366
2022 Q4	$37.3K	Buy	10,284 +3,109	+43%	+$13.8K	﹤0.01%	4647
2022 Q3	$34K	Sell	7,175 -107	-1%	-$538	﹤0.01%	3901
2022 Q2	$35K	Sell	7,282 -402	-5%	-$2.44K	﹤0.01%	4187
2022 Q1	$49K	Buy	+7,684	New	+$41.4K	﹤0.01%	4129

Barclays's THRN Position: Q4 2023 in Review

Barclays sold out of Thorne Healthtech, Inc. Common Stock (THRN) in Q4 2023, closing a stake of 51,089 shares — an estimated $521K sold.

Barclays first reported a position in THRN in Q1 2022 and held it in 7 quarters. The position peaked at $521K in Q3 2023. 0 funds tracked by Wall St. Rank hold THRN as of Q4 2023.

Barclays reported no remaining Thorne Healthtech, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Barclays sold 51,089 Thorne Healthtech, Inc. Common Stock shares in Q4 2023, an estimated $521K.
Barclays first reported a position in Thorne Healthtech, Inc. Common Stock in Q1 2022 and held it in 7 quarters.
Barclays's Thorne Healthtech, Inc. Common Stock position peaked at $521K in Q3 2023.
0 funds tracked by Wall St. Rank held Thorne Healthtech, Inc. Common Stock as of Q4 2023.

Based on Barclays's 13F filing for Q4 2023, filed 15 Feb 2024.